{
    "root": "357d8682-acdb-c640-e063-6294a90a4c09",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Amoxicillin",
    "value": "20250509",
    "ingredients": [
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30",
            "drugbank_id": "https://go.drugbank.com/drugs/DB14077"
        },
        {
            "name": "TALC",
            "code": "7SEV7J4R1U",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_32178"
        },
        {
            "name": "D&C YELLOW NO. 10",
            "code": "35SW5USQ3G"
        },
        {
            "name": "FD&C RED NO. 40",
            "code": "WZB9127XOA"
        },
        {
            "name": "GELATIN",
            "code": "2G86QN327L",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_5291"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_32234"
        },
        {
            "name": "METHYLPARABEN",
            "code": "A2I8C7HI9T",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_31835"
        },
        {
            "name": "PROPYLPARABEN",
            "code": "Z8IX2SC1OH",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_32063"
        },
        {
            "name": "SODIUM LAURYL SULFATE",
            "code": "368GB5141J",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_16189"
        },
        {
            "name": "FERROSOFERRIC OXIDE",
            "code": "XM0M87F357",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_50821"
        },
        {
            "name": "PROPYLENE GLYCOL",
            "code": "6DC9Q167V3",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_13643"
        },
        {
            "name": "SHELLAC",
            "code": "46N107B71O"
        },
        {
            "name": "AMMONIA",
            "code": "5138Q19F1X",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_16134"
        },
        {
            "name": "POTASSIUM HYDROXIDE",
            "code": "WZH3C48M4T",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_32035"
        },
        {
            "name": "AMOXICILLIN",
            "code": "804826J2HU",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_2676"
        }
    ],
    "indications": {
        "text": "adults pediatric patients upper respiratory tract infections ear , nose , throat : amoxicillin tablets , amoxicillin oral suspension , amoxicillin tablets ( chewable ) , amoxicillin capsules indicated treatment infections due susceptible ( \u03b2-lactamase-negative ) isolates streptococcusspecies . ( \u03b1- \u03b2-hemolytic isolates ) , streptococcus pneumoniae , staphylococcusspp . , haemophilus influenzae . infections genitourinary tract : amoxicillin tablets , amoxicillin oral suspension , amoxicillin tablets ( chewable ) , amoxicillin capsules indicated treatment infections due susceptible ( \u03b2-lactamase-negative ) isolates escherichia coli , proteus mirabilis , enterococcus faecalis . infections skin skin structure : amoxicillin tablets , amoxicillin oral suspension , amoxicillin tablets ( chewable ) , amoxicillin capsules indicated treatment infections due susceptible ( \u03b2-lactamase-negative ) isolates streptococcusspp . ( \u03b1- \u03b2-hemolytic isolates ) , staphylococcusspp . , e. coli . infections lower respiratory tract : amoxicillin tablets , amoxicillin oral suspension , amoxicillin tablets ( chewable ) , amoxicillin capsules indicated treatment infections due susceptible ( \u03b2-lactamase-negative ) isolates streptococcusspp . ( \u03b1- \u03b2-hemolytic isolates ) , s. pneumoniae , staphylococcusspp . , h. influenzae . adult patients helicobacter pyloriinfection duodenal ulcer disease : triple therapy helicobacter pylori ( h. pylori ) clarithromycin lansoprazole : amoxicillin , combination clarithromycin plus lansoprazole triple therapy , indicated treatment patients h. pyloriinfection duodenal ulcer disease ( active 1-year history duodenal ulcer ) eradicate h. pylori . eradication h. pylorihas shown reduce risk duodenal ulcer recurrence . dual therapy h. pyloriwith lansoprazole : amoxicillin , combination lansoprazole delayed-release capsules dual therapy , indicated treatment patients h. pyloriinfection duodenal ulcer disease ( active 1-year history duodenal ulcer ) either allergic intolerant clarithromycin resistance clarithromycin known suspected . ( clarithromycin package insert , microbiology . ) eradication h. pylorihas shown reduce risk duodenal ulcer recurrence . usage reduce development drug-resistant bacteria maintain effectiveness amoxicillin antibacterial drugs , amoxicillin used treat infections proven strongly suspected caused bacteria . culture susceptibility information available , considered selecting modifying antibacterial therapy . absence data , local epidemiology susceptibility patterns may contribute empiric selection therapy .",
        "doid_entities": [
            {
                "text": "duodenal ulcer (DOID:1724)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_1724"
            },
            {
                "text": "disease (DOID:4)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_4"
            }
        ],
        "orphanet_entities": [
            {
                "disease": "pyloriinfection",
                "orphanet_id": "http://www.orpha.net/ORDO/Orphanet_662405"
            }
        ]
    },
    "contraindications": {
        "text": "adults , 750 1750 mg/day divided doses every 8 12 hours . pediatric patients 3 months age , 20 45 mg/kg/day divided doses every 8 12 hours . refer full prescribing information dosing regimens . ( 2.2 , 2.3 ) upper dose neonates infants aged 3 months younger 30 mg/kg/day divided every 12 hours . ( 2.3 ) dosing h. pylori infection ( adults ) : triple therapy : 1 gram amoxicillin , 500 mg clarithromycin , 30 mg lansoprazole , given twice daily ( every 12 hours ) 14 days . dual therapy : 1 gram amoxicillin 30 mg lansoprazole , given three times daily ( every 8 hours ) 14 days . ( 2.4 ) reduce dose patients severe renal impairment ( gfr greater 30 ml/min ) . ( 2.5 )",
        "doid_entities": [],
        "orphanet_entities": [
            {
                "disease": "severe renal impairment",
                "orphanet_id": "http://www.orpha.net/ORDO/Orphanet_447788"
            }
        ]
    },
    "warningsAndPrecautions": "amoxicillin capsules , usp 500 mg : opaque buff cap opaque buff body , hard gelatin capsules . printed black \u201c teva \u201d cap \u201c 3109 \u201d body portions capsules contain 500 mg amoxicillin , usp trihydrate . available bottles 30 ( ndc 42708-010-30 ) . store 20\u00b0 25\u00b0c ( 68\u00b0 77\u00b0f ) [ usp controlled room temperature ] . dispense tight , light-resistant container defined usp , child-resistant closure ( required ) . keep medications reach children .",
    "adverseReactions": "amoxicillin contraindicated patients experienced serious hypersensitivity reaction ( e.g . , anaphylaxis stevens-johnson syndrome ) amoxicillin \u03b2-lactam antibacterial drugs ( e.g . , penicillins cephalosporins ) .",
    "indications_original": "Adults and Pediatric Patients\n                  \n                  \n                     \n                        Upper Respiratory Tract Infections of the Ear, Nose, and Throat:Amoxicillin tablets, amoxicillin for oral suspension, amoxicillin tablets (chewable), and amoxicillin capsules are indicated in the treatment of infections due to susceptible (ONLY \u03b2-lactamase-negative) isolates of\n  \n   Streptococcusspecies. (\u03b1- and \u03b2-hemolytic isolates only),\n  \n   Streptococcus pneumoniae,\n  \n   Staphylococcusspp., or\n  \n   Haemophilus influenzae.\n \n  \n                     \n                        Infections of the Genitourinary Tract:Amoxicillin tablets, amoxicillin for oral suspension, amoxicillin tablets (chewable), and amoxicillin capsules are indicated in the treatment of infections due to susceptible (ONLY \u03b2-lactamase-negative) isolates of\n  \n   Escherichia coli,\n  \n   Proteus mirabilis, or\n  \n   Enterococcus faecalis.\n \n  \n                     \n                        Infections of the Skin and Skin Structure:Amoxicillin tablets, amoxicillin for oral suspension, amoxicillin tablets (chewable), and amoxicillin capsules are indicated in the treatment of infections due to susceptible (ONLY \u03b2-lactamase-negative) isolates of\n  \n   Streptococcusspp. (\u03b1- and \u03b2-hemolytic isolates only),\n  \n   Staphylococcusspp., or\n  \n   E. coli.\n \n  \n                     \n                        Infections of the Lower Respiratory Tract:Amoxicillin tablets, amoxicillin for oral suspension, amoxicillin tablets (chewable), and amoxicillin capsules are indicated in the treatment of infections due to susceptible (ONLY \u03b2-lactamase-negative) isolates of\n  \n   Streptococcusspp. (\u03b1- and \u03b2-hemolytic isolates only),\n  \n   S. pneumoniae,\n  \n   Staphylococcusspp., or\n  \n   H. influenzae.\n \n  \n                  \n                  \n                     Adult Patients only\n                  \n                  \n                     \n                        \n                           Helicobacter pyloriInfection and Duodenal Ulcer Disease: \n    \n                        \n                        \n                             Triple therapy for\n   \n    Helicobacter pylori (H. pylori)with clarithromycin and lansoprazole: \n    \n                        Amoxicillin, in combination with clarithromycin plus lansoprazole as triple therapy, is indicated for the treatment of patients with\n  \n   H. pyloriinfection and duodenal ulcer disease (active or 1-year history of a duodenal ulcer) to eradicate\n  \n   H. pylori. Eradication of\n  \n   H. pylorihas been shown to reduce the risk of duodenal ulcer recurrence. \n   \n                        \n                             Dual therapy for\n   \n    H. pyloriwith lansoprazole: \n    \n                        Amoxicillin, in combination with lansoprazole delayed-release capsules as dual therapy, is indicated for the treatment of patients with\n  \n   H. pyloriinfection and duodenal ulcer disease (active or 1-year history of a duodenal ulcer)\n  \n   who are either allergic or intolerant to clarithromycin or in whom resistance to clarithromycin is known or suspected.(See the clarithromycin package insert, MICROBIOLOGY.) Eradication of\n  \n   H. pylorihas been shown to reduce the risk of duodenal ulcer recurrence.\n \n  \n                  \n                  \n                     Usage\n                     \n                  \n                  To reduce the development of drug-resistant bacteria and maintain the effectiveness of amoxicillin and other antibacterial drugs, amoxicillin should be used only to treat infections that are proven or strongly suspected to be caused by bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.",
    "contraindications_original": "In Adults, 750 to 1750 mg/day in divided doses every 8 to 12 hours. In Pediatric Patients over 3 Months of Age, 20 to 45 mg/kg/day in divided doses every 8 to 12 hours. Refer to full prescribing information for specific dosing regimens. ( 2.2 , 2.3 ) The upper dose for neonates and infants aged 3 months or younger is 30 mg/kg/day divided every 12 hours. ( 2.3 ) Dosing for H. pylori Infection (in Adults): Triple therapy: 1 gram amoxicillin, 500 mg clarithromycin, and 30 mg lansoprazole, all given twice daily (every 12 hours) for 14 days. Dual therapy: 1 gram amoxicillin and 30 mg lansoprazole, each given three times daily (every 8 hours) for 14 days. ( 2.4 ) Reduce the dose in patients with severe renal impairment (GFR greater than 30 mL/min). ( 2.5 )",
    "warningsAndPrecautions_original": "Amoxicillin Capsules, USP\n                  \n                  \n                     500 mg: Opaque buff cap and opaque buff body, hard gelatin capsules. Printed black \u201cTEVA\u201d on cap and \u201c3109\u201d on body portions of the capsules and contain 500 mg amoxicillin, USP as the trihydrate. They are available in bottles of 30 (NDC 42708-010-30).\n \n                  Store at 20\u00b0 to 25\u00b0C (68\u00b0 to 77\u00b0F) [See USP Controlled Room Temperature].\n                  Dispense in a tight, light-resistant container as defined in the USP, with a child-resistant closure (as required).\n                  Keep this and all medications out of the reach of children.",
    "adverseReactions_original": "Amoxicillin is contraindicated in patients who have experienced a serious hypersensitivity reaction (e.g., anaphylaxis or Stevens-Johnson syndrome) to amoxicillin or to other \u03b2-lactam antibacterial drugs (e.g., penicillins and cephalosporins).",
    "drug": [
        {
            "name": "Amoxicillin",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_2676"
        }
    ]
}